Novo Nordisk is rated a Strong Buy as it shifts to a high-volume, lower-price model, improving operational efficiency and leveraging AI for cost savings. Recent FDA approvals for Wegovy HD and Awiqli, along with a strategic partnership with OpenAI, support ongoing innovation and supply chain independence. Despite challenges like patent expirations and price pressures, the company's valuation remains attractive with a P/E of 12.29 and a free cash flow yield near 4.7%. Upcoming catalysts include growth in US Wegovy volumes, oral Wegovy rollout, potential share buybacks, and new obesity therapy developments.
Novo Nordisk's adjusted revenue fell 10.3% year-over-year, mainly due to weaker sales of Ozempic and Rybelsus, although profitability and cash flow have improved. The company’s drug pipeline in obesity and diabetes shows promise with candidates like ...
Novo Resources Corp's initial reverse circulation drilling at its Wyloo Polymetallic Project in Western Australia uncovered a significant hydrothermal alteration system with high-grade silver and antimony mineralisation from surface. This discovery i...
Eli Lilly announced plans to file for FDA approval of retatrutide, a new weight-loss drug, following phase 3 trials where participants lost an average of nearly 56 pounds over 80 weeks. The drug targets multiple hormones affecting appetite and metabo...
Novo Resources has filed a technical report confirming the mineral resource estimate for the Leven Star Reef gold project in Victoria, Australia, matching earlier estimates. Additionally, drilling at the Wyloo Polymetallic Project in Western Australi...
Novo Resources Corp. has filed a technical report on the Mineral Resource Estimate for the Leven Star Reef at its 100% owned Belltopper Gold Project in Victoria, Australia. The report, prepared by qualified experts, confirms the previously announced ...
